NCT03533387View on ClinicalTrials.gov

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 11, 2018

Primary Completion Date

July 6, 2018

Study Completion Date

September 30, 2018

Conditions

Healthy Volunteers

Interventions

DRUG

MN-166

an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years

Trial Locations (1)

90630

WCCT Global, Inc., Cypress